Cargando…

Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes

BACKGROUND: Serum fatty acid-binding protein 4 (FABP4), as an intracellular lipid chaperone and adipokine, was reported to be related to the incidence of type 2 diabetes (T2D) and diabetic complications, but its association with pancreatic islet β-cell and α-cell functions has not been fully elucida...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong, Cao, Jie, Su, Jian-bin, Wang, Xue-qin, Wang, Xing, Zhang, Dong-mei, Wang, Xiao-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234651/
https://www.ncbi.nlm.nih.gov/pubmed/34174950
http://dx.doi.org/10.1186/s13098-021-00690-z
Descripción
Sumario:BACKGROUND: Serum fatty acid-binding protein 4 (FABP4), as an intracellular lipid chaperone and adipokine, was reported to be related to the incidence of type 2 diabetes (T2D) and diabetic complications, but its association with pancreatic islet β-cell and α-cell functions has not been fully elucidated. So the present study was to investigate the serum FABP4 levels and responses of islet β-cells and α-cells in patients with T2D. METHODS: 115 patients with T2D and 89 healthy controls (HC), who received serum FABP4 levels test, were recruited to participate in this study. Moreover, 75-g oral glucose tolerance test (OGTT) was performed in T2D patients to evaluate islet β-cell and α-cell functions. Systemic insulin sensitivity and overall insulin secretion of islet β-cell function were assessed by Matsuda index using C peptide (ISI(M-cp)) and ratio of the area under the C peptide curve to the glucose curve (AUC(cp/glu)) during OGTT, respectively. Fasting glucagon (Gluca(0min)) and postchallenge glucagon assessed by the area under the glucagon curve (AUC(gluca)) were determined during OGTT to evaluate islet α-cell function. And other various clinical variables were also measured in all participants. Skewed variables were natural log-transformed (ln), such as lnFABP4. RESULTS: The serum FABP4 levels in T2D patients were significantly higher than those in HC (p < 0.05). And after partially adjusting for fasting plasma glucose, serum lnFABP4 levels were negatively correlated with lnISI(M-cp) (r =  − 0.332, p < 0.001) and positively correlated with lnAUC(cp/glu) (r = 0.324, p < 0.001), lnGluca(0min) (r = 0.200, p = 0.040) and lnAUC(gluca) (r = 0.311, p < 0.001), respectively, in patients with T2D. Furthermore, when multiple linear regression analyses were applied to adjust for other various clinical variables, serum lnFABP4 levels were found to remain associated with lnISI(M-cp) (β =  − 0.296, t =  − 2.900, p = 0.005), lnAUC(cp/glu) (β = 0.223, t = 2.038, p = 0.046), lnGluca(0min) (β = 0.272, t = 2.330, p = 0.024) and lnAUC(gluca) (β = 0.341, t = 3.065, p = 0.004), respectively. CONCLUSION: Increased serum FABP4 levels were closely associated with blunted insulin sensitivity, increased insulin secretion, and elevated fasting and postchallenge glucagon levels in patients with T2D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-021-00690-z.